Loading...
•
Jun 30, 2021
Roivant Sciences Q1 2022 Earnings Report
Roivant Sciences reported financial results for the first fiscal quarter of 2021 and provided a business update.
Key Takeaways
Roivant Sciences reported its financial results for the fiscal quarter ended June 30, 2021. The company highlighted the upcoming closing of the business combination with MAAC, the FDA's acceptance of Dermavant's NDA, the dosing of the first patient in a Phase 3 trial, the completion of Datavant's merger with Ciox Health, and a strategic investment in Immunovant.
Roivant is on track to close business combination with Montes Archimedes Acquisition Corp. and commence trading on Nasdaq on October 1 under the symbol “ROIV”.
Dermavant’s NDA for tapinarof for the treatment of plaque psoriasis accepted for filing by FDA.
First patient dosed in Phase 3 Dermavant trial of tapinarof for the treatment of atopic dermatitis.
Datavant completed its merger with Ciox Health; Roivant received approximately $320 million in cash and a minority equity stake.
Roivant Sciences
Roivant Sciences
Forward Guidance
Roivant anticipates several milestones across its portfolio of companies.
Positive Outlook
- Roivant expects to close its business combination with MAAC and commence trading on Nasdaq on October 1.
- Dermavant anticipates a decision from the FDA on tapinarof for plaque psoriasis in Q2 2022 and topline data from a Phase 3 trial for atopic dermatitis in H1 2023.
- Immunovant plans to initiate a pivotal trial for myasthenia gravis in early 2022.
- Immunovant also plans to announce at least two new indications and submit INDs with trial designs to the FDA over the next 12 months.
- Aruvant anticipates reporting additional clinical data from the Phase 1/2 trial of ARU-1801 in sickle cell disease patients in H2 2021.